Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02343575 · ClinicalTrials.gov registry record · Phase 4
Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU
A Phase 4 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT02343575: Clinical Trial Phase 4 study, sponsored by Stanford University.
NCT02343575 is a Phase 4 study that was terminated before completion, run by Stanford University. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02343575, a Phase 4 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
Delirium is the most often encountered psychiatric diagnosis in the general hospital, with incidence up to 85% in the intensive care unit (ICU) setting and with significant consequences on patients' morbidity and mortality. Currently, although not FDA approved, antipsychotics are often considered the first-line pharmacological treatment. However, there can be limitations to their use, including side effects or lack of efficacy. Valproic acid (VPA) is one of the alternatives at times used in such patients which from limited case series data appears to be helpful and tolerated. VPA can provide relief from agitation that poses a threat to the safety and recovery of the patient. Moreover, mechanistically it addresses the neurochemical and cellular abnormalities inherent in delirium (it has NMDA-antagonist, anti-dopaminergic, GABAergic,anti-inflammatory, anti-apoptotic, and histone deacetylase inhibitor properties, among others). The purpose of this study is to evaluate the efficacy and tolerability of the VPA in the first known to us randomized controlled trial.
Interventions
- DRUG Placebo
- DRUG Haloperidol
- DRUG Valproic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-01 |
| Est. Completion | 2018-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02343575
The ClinicalTrials.gov registry entry for NCT02343575 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02343575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02343575 about?
NCT02343575 is a clinical study titled "Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU". Delirium is the most often encountered psychiatric diagnosis in the general hospital, with incidence up to 85% in the intensive care unit (ICU) setting and with significant consequences on patients' morbidity and mortality. Currently, although not FDA approved, antipsychotics are often considered th...
What is the current status of trial NCT02343575?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2015-01. Estimated completion is 2018-01.
What interventions are being tested in trial NCT02343575?
The interventions under investigation include: Placebo (DRUG), Haloperidol (DRUG), Valproic Acid (DRUG).
Who is sponsoring clinical trial NCT02343575?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.